These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22397670)

  • 61. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene.
    El-Harith el-HA; Roesl C; Ballmaier M; Germeshausen M; Frye-Boukhriss H; von Neuhoff N; Becker C; Nürnberg G; Nürnberg P; Ahmed MA; Hübener J; Schmidtke J; Welte K; Stuhrmann M
    Br J Haematol; 2009 Jan; 144(2):185-94. PubMed ID: 19036112
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
    Szpurka H; Tiu R; Murugesan G; Aboudola S; Hsi ED; Theil KS; Sekeres MA; Maciejewski JP
    Blood; 2006 Oct; 108(7):2173-81. PubMed ID: 16741247
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Lewandowski K; Gniot M; Wojtaszewska M; Kanduła Z; Becht R; Paczkowska E; Mędraś E; Wasilewska E; Iwoła M
    Int J Lab Hematol; 2018 Jun; 40(3):366-371. PubMed ID: 29508552
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.
    Al-Harbi T; Al-Zahrani M; Al-Balwi M; Al-Hazmi A; Alsuhaibani A; Aljafn N; Alsumari F; Aleshaiwi L; Alsuhibani A; Alqasim O; Ahmad N
    Br J Haematol; 2021 Sep; 194(5):893-898. PubMed ID: 34131895
    [TBL] [Abstract][Full Text] [Related]  

  • 65. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.
    Brooks SA; Luty SB; Lai HY; Morse SJ; Nguyen TK; Royer LR; Agarwal A; Druker BJ; Fleischman AG
    Exp Hematol; 2016 Jan; 44(1):24-9.e1. PubMed ID: 26458983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
    Garber K
    J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
    [No Abstract]   [Full Text] [Related]  

  • 67. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 68. JAK2 V617F due to a novel TG --> CT mutation at nucleotides 1848-1849: diagnostic implication.
    Wong CL; Ma ES; Wang CL; Lam HY; Ma SY
    Leukemia; 2007 Jun; 21(6):1344-6. PubMed ID: 17344912
    [No Abstract]   [Full Text] [Related]  

  • 69. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Remacha AF; Nomdedéu JF; Puget G; Estivill C; Sarda MP; Canals C; Aventin A
    Haematologica; 2006 May; 91(5):719-20. PubMed ID: 16670082
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation.
    Au WY; Fung A; Lam KY; Lie AK; Liang R; Kwong YL
    Bone Marrow Transplant; 2006 Oct; 38(8):573-4. PubMed ID: 16953212
    [No Abstract]   [Full Text] [Related]  

  • 71. Thrombocytosis and coronary occlusion.
    Nanavati A; Patel N; Burke J
    JACC Cardiovasc Interv; 2012 Jun; 5(6):e18-9. PubMed ID: 22721672
    [No Abstract]   [Full Text] [Related]  

  • 72. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.
    Giona F; Teofili L; Moleti ML; Martini M; Palumbo G; Amendola A; Mazzucconi MG; Testi AM; Pignoloni P; Orlando SM; Capodimonti S; Nanni M; Leone G; Larocca LM; Foà R
    Blood; 2012 Mar; 119(10):2219-27. PubMed ID: 22262773
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Familial polycythemia vera with non-germline JAK2(V617F) mutation sparing the abnormal and clonal granulopoiesis.
    Hussein K; Bock O; Ballmaier M; Göhring G; Steinemann D; Lehmann U; Kemper J; Buhr T; Kreipe H
    Leukemia; 2007 Dec; 21(12):2566-8. PubMed ID: 17625610
    [No Abstract]   [Full Text] [Related]  

  • 74. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].
    Remacha AF; Puget G; Nomdedéu JF; Estivill C; Sardà MP; Canals C
    Med Clin (Barc); 2006 Oct; 127(16):601-4. PubMed ID: 17145024
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
    Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
    Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of JAK2 mutations in RARS and other MDS.
    Hellström-Lindberg E; Cazzola M
    Hematology Am Soc Hematol Educ Program; 2008; ():52-9. PubMed ID: 19074058
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A novel thrombopoietin (THPO) mutation altering mRNA splicing in a case of familial thrombocytosis.
    Prouzet-Mauléon V; Montibus B; Chauveau A; Hautin M; Migeon M; Ka C; Laharanne E; Bidet A; Corcos L; Lippert E
    Br J Haematol; 2020 Jul; 190(2):e104-e107. PubMed ID: 32430933
    [No Abstract]   [Full Text] [Related]  

  • 79. Splenomegaly and the JAK2 V617F mutation.
    Langabeer SE
    Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
    [No Abstract]   [Full Text] [Related]  

  • 80. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Broséus J; Alpermann T; Wulfert M; Florensa Brichs L; Jeromin S; Lippert E; Rozman M; Lifermann F; Grossmann V; Haferlach T; Germing U; Luño E; Girodon F; Schnittger S;
    Leukemia; 2013 Sep; 27(9):1826-31. PubMed ID: 23594705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.